144 related articles for article (PubMed ID: 11378341)
1. A pilot study of whole body hyperthermia and carboplatin in platinum-resistant ovarian cancer.
Westermann AM; Grosen EA; Katschinski DM; Jäger D; Rietbroek R; Schink JC; Tiggelaar CL; Jäger E; Zum Vörde sive Vörding P; Neuman A; Knuth A; Van Dijk JD; Wiedemann GJ; Robins HI
Eur J Cancer; 2001 Jun; 37(9):1111-7. PubMed ID: 11378341
[TBL] [Abstract][Full Text] [Related]
2. Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer - a phase II study.
Atmaca A; Al-Batran SE; Neumann A; Kolassa Y; Jäger D; Knuth A; Jäger E
Gynecol Oncol; 2009 Feb; 112(2):384-8. PubMed ID: 19059635
[TBL] [Abstract][Full Text] [Related]
3. Whole-body hyperthermia in combination with platinum-containing drugs in patients with recurrent ovarian cancer.
Douwes F; BogoviC J; Douwes O; Migeod F; Grote C
Int J Clin Oncol; 2004 Apr; 9(2):85-91. PubMed ID: 15108039
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical trial of carboplatin and 41.8 degrees C whole-body hyperthermia in cancer patients.
Robins HI; Cohen JD; Schmitt CL; Tutsch KD; Feierabend C; Arzoomanian RZ; Alberti D; d'Oleire F; Longo W; Heiss C
J Clin Oncol; 1993 Sep; 11(9):1787-94. PubMed ID: 8355046
[TBL] [Abstract][Full Text] [Related]
5. Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: a phase II study.
Chambers SK; Davis CA; Schwartz PE; Kohorn EI; Chambers JT
Clin Cancer Res; 1996 Oct; 2(10):1693-7. PubMed ID: 9816118
[TBL] [Abstract][Full Text] [Related]
6. Abdomino-pelvic hyperthermia and intraperitoneal carboplatin in epithelial ovarian cancer: feasibility, tolerance and pharmacology.
Formenti SC; Shrivastava PN; Sapozink M; Jozsef G; Chan KK; Jeffers S; Morrow PC; Muggia FM
Int J Radiat Oncol Biol Phys; 1996 Jul; 35(5):993-1001. PubMed ID: 8751408
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients.
Chambers SK; Davis CA; Chambers JT; Schwartz PE; Lorber MI; Hschumacher RE
Clin Cancer Res; 1996 Oct; 2(10):1699-704. PubMed ID: 9816119
[TBL] [Abstract][Full Text] [Related]
8. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer.
Steller MA; Egorin MJ; Trimble EL; Bartlett DL; Zuhowski EG; Alexander HR; Dedrick RL
Cancer Chemother Pharmacol; 1999; 43(2):106-14. PubMed ID: 9923815
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of carboplatin and whole body hyperthermia (WBH) in recurrent and metastatic cervical cancer.
Richel O; Zum Vörde Sive Vörding PJ; Rietbroek R; Van der Velden J; Van Dijk JD; Schilthuis MS; Westermann AM
Gynecol Oncol; 2004 Dec; 95(3):680-5. PubMed ID: 15581981
[TBL] [Abstract][Full Text] [Related]
10. Ifosfamide and carboplatin combined with 41.8 degrees C whole-body hyperthermia in patients with refractory sarcoma and malignant teratoma.
Wiedemann GJ; d'Oleire F; Knop E; Eleftheriadis S; Bucsky P; Feddersen S; Klouche M; Geisler J; Mentzel M; Schmucker P
Cancer Res; 1994 Oct; 54(20):5346-50. PubMed ID: 7923163
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
12. Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer.
van der Burg ME; Vergote I; Onstenk W; Boere IA; Leunen K; van Montfort CA; van Doorn HC
Eur J Cancer; 2013 Apr; 49(6):1254-63. PubMed ID: 23276720
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer.
Morgan RJ; Synold TW; Gandara D; Muggia F; Scudder S; Reed E; Margolin K; Raschko J; Leong L; Shibata S; Tetef M; Vasilev S; McGonigle K; Longmate J; Yen Y; Chow W; Somlo G; Carroll M; Doroshow JH
Cancer Chemother Pharmacol; 2004 Oct; 54(4):283-9. PubMed ID: 15184995
[TBL] [Abstract][Full Text] [Related]
14. Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot study.
Argenta PA; Sueblinvong T; Geller MA; Jonson AL; Downs LS; Carson LF; Ivy JJ; Judson PL
Gynecol Oncol; 2013 Apr; 129(1):81-5. PubMed ID: 23352917
[TBL] [Abstract][Full Text] [Related]
15. A Systemic Hyperthermia Oncologic Working Group trial. Ifosfamide, carboplatin, and etoposide combined with 41.8 degrees C whole-body hyperthermia for metastatic soft tissue sarcoma.
Westermann AM; Wiedemann GJ; Jager E; Jager D; Katschinski DM; Knuth A; Vörde Sive Vörding PZ; Van Dijk JD; Finet J; Neumann A; Longo W; Bakhshandeh A; Tiggelaar CL; Gillis W; Bailey H; Peters SO; Robins HI;
Oncology; 2003; 64(4):312-21. PubMed ID: 12759526
[TBL] [Abstract][Full Text] [Related]
16. A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer.
Adachi S; Ogasawara T; Ito K; Koyama M; Nagano T; Suzuki A; Yamada T; Nakata Y; Ozawa M
Oncol Rep; 2001; 8(2):285-8. PubMed ID: 11182041
[TBL] [Abstract][Full Text] [Related]
17. Effect of whole body hyperthermia on carboplatin disposition and toxicity in dogs.
Page RL; McEntee MC; Williams PL; George SL; Price GS; Novotney CA; Hauck ML; Riviere JE; Dewhirst MW; Thrall DE
Int J Hyperthermia; 1994; 10(6):807-16. PubMed ID: 7884240
[TBL] [Abstract][Full Text] [Related]
18. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
[TBL] [Abstract][Full Text] [Related]
19. A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer.
Leiser AL; Maluf FC; Chi DS; Sabbatini P; Hensley ML; Schwartz L; Venkatraman E; Spriggs D; Aghajanian C
Int J Gynecol Cancer; 2007; 17(2):379-86. PubMed ID: 17362316
[TBL] [Abstract][Full Text] [Related]
20. Optimal duration of whole body hyperthermia when combined with cis-diaminne-1,1-cychlobutane dicarboxylate platinum (II) (carboplatin).
Kaneko T; Sakaguchi Y; Makino M; Matsuda H; Strebel FR; Jenkins GN; Bull JM
Anticancer Res; 1997; 17(3C):1897-901. PubMed ID: 9216642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
